Pharma News

AbbVie , a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases will collaborate to develop and commercialize ARGX-115. ARGX-115 is argenx' preclinical-stage human antibody program targeting the novel immuno-oncology target GARP, a protein believed to contribute to immuno-suppressive effects of T-cell

AbbVie and CytomX Therapeutics, Inc. announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). CD71 is highly expressed in a number of solid and hematologic cancers and has attractive molecular properties for efficient delivery of cytotoxic payloads to tumor cells. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

AstraZeneca and its global biologics research and development arm, MedImmune, announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline.

GW Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC).

In a new study, University of Massachusetts Amherst researchers Krishna Poudel and colleagues report that zinc deficiency may contribute to chronic inflammation among HIV-positive individuals. Theirs is believed to be the first investigation to explore the association between serum zinc levels and inflammation among people with human immunodeficiency virus (HIV) infection, while taking their anti-retroviral therapy (ART) into account.

The most aggressive form of pancreatic cancer often described as one of the hardest malignancies to diagnose and treat thrives in the presence of neighboring tumor cells undergoing a particular form of "orchestrated cell death." This is according to a major study recently published in the journal Nature.

Examining the poorly understood link between obstructive sleep apnea (OSA) and type 2 diabetes complications, researchers identified specific measures of low blood oxygenation that are associated with impaired kidney function and diabetic nephropathy.

[adsense:336x280:8701650588]

Investigating disparities in the composition of the estrobolome, the gut bacterial genes capable of metabolizing estrogens in both healthy individuals and in women diagnosed with estrogen-driven breast cancer may lead to the development of microbiome-based biomarkers that could help mitigate the risk of certain cancers, according to a review paper published April 22 in the JNCI: Journal of the National Cancer Institute.

In September 2015, then 44 year-old CEO of BioViva USA Inc. Elizabeth Parrish received two of her own company's experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.